Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma

Yuelong Liang, Jiang Chen, Qingsong Yu, Tong Ji, Bin Zhang, Junjie Xu, Yi Dai, Yangyang Xie, Hui Lin, Xiao Liang & Xiujun Cai

Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, China

Abstract

Sorafenib, the only approved drug for hepatocellular carcinoma, acts as a remarkable inhibitor of Raf serine-threonine kinases. However, Sorafenib is expensive, and clinical experience shows that it is not an effective treatment for many patients. Previous study has demonstrated that phosphorylated ERK (pERK) is a key downstream component in the RAF/MEK/ERK signaling pathway. Here, we investigate whether pERK is a useful biomarker for treating HCC with Sorafenib. In vitro cell viability assays showed that the efficacy of Sorafenib was distinctly different according to the level of pERK. Furthermore, in established patient-derived xenografts from HCC specimens, we found that the growth rate of tumors with high levels of pERK was significantly decreased by Sorafenib treatment. Taken together, pERK is a potential biomarker for the sensitivity to Sorafenib in treating HCC.
Introduction

Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide. Due to its high malignancy, HCC is the third leading cause of cancer-related mortality worldwide [1], and in China, it ranks second. An epidemiological statistic published in the New English Journal of Medicine stated that a great majority of HCC patients experience relapse, with a 5-year survival rate not more than 10% [2]. Unfortunately, there are no new treatments that can improve survival in patients with advanced hepatocellular carcinoma, and HCC is not sensitive to either chemotherapy or radiotherapy [3, 4].

The development of targeted therapies for cancers, such as trastuzumab (against HER2-positive breast cancer) [5, 6], tamoxifen (against estrogen receptor-positive breast cancer) [7] and cetuximab (against EGFR-positive non-small-cell lung carcinoma) [8], has a strong positive response on improving disease-free survival and overall survival for cancer patients. Therefore, new targeted therapies for HCC are both promising and urgently needed.

As a multi-kinase inhibitor, Sorafenib inhibits Raf serine/threonine kinase and afterward blocks the Raf/MEK/ERK pathway. Sorafenib is the only molecularly targeted agent that has been confirmed as efficacious in treating advanced HCC. In phase III and phase II trials, Sorafenib exhibits significant survival benefits for patients with advanced HCC [9, 10]. Even so, the efficacy of Sorafenib in treatment of HCC remains moderate and patients survival is short following Sorafenib treatment [11]. Sorafenib therapy is both expensive [12] and unsatisfactory [13]. There is an urgent need for a powerful new biomarker to predict sensitivity to Sorafenib in HCC therapy.

In this research, the relationship between expression levels of phosphorylated ERK, a well known key downstream factor in the RAF/MEK/ERK signaling pathway, and Sorafenib response was examined using cell lines and patient-derived primary HCC xenografts in a mouse model. The results demonstrated that HCC characterized by higher levels of pERK are more sensitive to Sorafenib. Our study indicates that pERK levels may be used to predict the efficacy of Sorafenib in treating HCC.

Materials and Methods

Chemicals and other reagents

Sorafenib was weighed and stored in dry form away from light. For in vitro experiments, the Sorafenib was dissolved in DMSO, and the concentration of DMSO was kept under 0.1%. For in vivo experiments, Sorafenib was dissolved in 50% cremophor EL (Sigma, St Louis, Mo) and 50% ethanol. The compounds were sonicated for 5–10 min. The aqueous mixture (75% water) was gradually added and the final dosing solution was generated [14]. 30 mg/kg of the above mixture was administered daily by oral gavage.

Cell culture

HepG2 cell line was obtained from ATCC. Primary cell HCC-0010 was gained from Patient-derived xenografts (by Professor Cang Yong). All cells were grown in appropriate medium containing 10% fetal bovine serum. Cells were cultured in a humidified 37°C incubator with an atmosphere of 5% CO₂. CCK-8 (Dojindo, Kumamoto, Japan) was used to test the proliferative potential of HCC cells.

Patient samples

Use of human tissues was approved by the Sir Run Run Shaw Hospital ethical committee. Written informed consent was obtained from each patient. Specimens of the patients were collected from those undergoing liver resection for HCC at the Sir Run Run Shaw Hospital (Zhejiang University, Hangzhou, China).

Patient-derived primary HCC xenografts model

Patient-derived xenografts were implanted subcutaneously into nude mice (female, age 6–8 weeks). Tumor growth was monitored, and dimensions of xenografts were measured after 1 month of Sorafenib treatment. The following formula was used to calculate tumor volume: (longest tumor diameter)² * (shortest tumor diameter)²/2.

All mice were maintained according to the Guide for the Care and Use of Laboratory Animals published by the NIH. Sterilized food and water ad libitum were provided. All mice were housed in negative pressure isolators with 12 h light/dark cycles.

Western blot

For whole protein extracts, cell samples, and tumor tissues were homogenized in Rapabuffer (sigma) with a protease inhibitor cocktail (Roche). The mixture was then incubated on ice for 30 min. Soon afterwards, the compounds were centrifuged for 15 min at 12,000g. 4–12% SDS–PAGE gel and nitrocellulose membrane (Invitrogen) were used to separate protein. The membranes, with the primary antibodies, were incubated overnight at 4°C. Immunoblots were developed using secondary antibodies such as anti-mouse- or anti-rabbit-HRP (SANTA CRUZ). Enhanced chemiluminescence (Pierce Biotechnology) was performed according to the instructions. The antibodies used for Western blotting included Phospho-p44/42 MAPK.
(Erk1/2) (Thr202/Tyr204) (Cell Signaling Technology, 1:2000), p44/42 MAPK (Erk1/2) (Cell Signaling Technology, 1:2000), β-actin (Cell Signaling Technology, 1:2000), SETD7 (Cell Signaling Technology, 1:1000).

**Immunohistochemistry**

Paraffin embedding was used to process specimens. Sections of 5 μm were prepared for subsequent experiments. Endogenous peroxidase activity and non-specific staining were blocked, then the sections were incubated overnight with primary antibodies at 4°C. The strepavidin-biotin peroxidase complex method was used according to the instructions (Lab Vision). The antibodies used for immunohistochemistry included Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling Technology, 1:200).

**Statistical analysis**

Mean ± SD were used to represent experimental data. An unpaired Student’s t-test or Mann–Whitney rank sum test was used to compare the two groups. The χ²-test was used to test the differences in mortality. P < 0.05 was considered as significant.

**Results**

The efficacy of Sorafenib in HCC was different between different levels of pERK in HepG2 cells and HCC-0010 cells

The western blot comparison shows that the Chinese origin cells (HCC-0010) contain significantly lower levels of pERK than HepG2 (Fig. 1A). The CCK-8 cell viability assay, used to measure the efficacy of Sorafenib against HCC showed that different HCC cell lines displayed distinct responses upon Sorafenib treatment (Fig. 1C). For instance, Sorafenib strikingly inhibited HepG2 cell proliferation in a dose-dependent manner, while HCC-0010 cells showed less sensitivity to Sorafenib-mediated proliferation inhibition (Fig. 1B).

**Basal pERK levels vary in HCC patients**

pERK is one of the most important key factors of the RAF/MEK/ERK pathway. To determine whether there is any relationship between basal pERK levels and the efficacy of Sorafenib on killing cells in vivo, pERK levels in different HCC patients were compared by immunohistochemistry (Fig. 2A) and western blot (Fig. 2B). The pERK expression levels were examined by immunohistochemistry in 66 HCC patient samples and only 20 patients (30.3%) showed high levels of expression.

**Effect of Sorafenib on tumor growth is correlated with basal pERK levels in patient-derived primary HCC xenograft models**

To further verify the relationship between pERK level and efficacy of Sorafenib, we selected five pairs of patient-derived primary HCC xenograft models according to the expression levels of pERK: I and II (high levels of pERK, No. 1-5; low levels of pERK, No. 6-10) to evaluate the effects of Sorafenib in vivo (Fig. 3A and B). Mice in these two groups were treated with either DMSO or 30 mg/kg Sorafenib daily by gavage and tumor sizes were measured after 1 month. The growth rate of tumors in group I mice had

---

**Figure 1.** Effects of Sorafenib on cell proliferation differ between HepG2 cells and HCC-0010 cells. (A) Basal pERK levels in different cell lines were measured by western blotting. (B–D) The effects of Sorafenib on cell proliferation were measured by the CCK-8 cell viability assay (means±SEM; *P<0.05).
obviously decreased with the Sorafenib treatment while Sorafenib treatment had little effect on tumor growth in group II mice (Fig. 4A and B). Tumors in Sorafenib-treated mice had shrunk obviously in Group I than in Group II, compared with the DMSO-treated controls (Fig. 4C).

**Gene expression was different between HepG2 cells and HCC-0010 cells**

To explore the underlying mechanisms, we carried out RNA-seq to discover gene expression changes with Sorafenib treatment. Either DMSO or 2 μmol/L Sorafenib were used to treat HepG2 and HCC-0010 cells for 24 h and RNA-seq was performed. We found that there were significantly more genes whose expression levels changed over fourfold after Sorafenib treatment in HepG2 cells than in HCC-0010 cells (Table 1). More interestingly, we also observed genes involved in several important tumor-associated pathways including the ALK pathway [15, 16], Lysine degradation [17] and ECM-receptor interaction [18] showed dramatically higher levels of expression in HCC-0010 cells compared with HepG2 cells (Fig. 5A, Table 2). This differential expression might explain the difference in sensitivity to Sorafenib between HCC-0010 and HepG2 cell lines. Real-time qPCR was used to verify the results of RNA-seq in cell lines, which showed that

---

**Figure 2.** Different levels of pERK in HCC patient samples were observed. Basal pERK levels in different HCC patients were measured by immunohistochemistry (A) and western blotting (B).

**Figure 3.** Patient-derived primary HCC xenografts models with different expression of pERK were established. Expression of pERK in patient-derived primary HCC xenograft models was verified by western blotting (B) and immunohistochemistry (A).
Lysine degradation associated genes (NSD1 and SETD7) might be the key factors (Fig. 5B).

**Down-regulation of SETD7 increased the sensitivity of HCC to Sorafenib**

Down-regulation of SETD7 by siRNA-SETD7 reduced the levels of protein expression compared with the Control/Scramble siRNA treated in HCC-0010 cells (Fig. 6A). Together, results shown in Figures 6B and C suggest that Sorafenib alone has little effect on HCC-0010, but the addition of siRNA-SETD7 enhances the efficacy of Sorafenib to suppress HCC cell proliferation. These results suggest that SETD7 plays an important role in the pERK− HCC that are resistant to Sorafenib.

**Discussion**

The Ras/Raf/MEK/ERK signaling cascade is involved in proliferation, transformation, mitogenesis and differentiation of cancer cells, and is frequently deregulated in tumorigenic diseases [19–22]. The RAF/MEK/ERK cascade plays a major role in the pathogenesis of HCC, and many inhibitors...
against this cascade, including small molecular inhibitors and monoclonal antibodies, have been developed to treat HCC [23]. Sorafenib (Nexavar, Bayer Health Care Pharmaceuticals) inhibits the Raf serine-threonine kinases and blocks the RAF/MEK/ERK signaling pathway [24]. It is the only known molecularly targeted agent approved for treatment of advanced HCC. However, clinical experience shows that Sorafenib is expensive and not all patients with HCC can obtain benefits from it. It was the urgent need to identify biomarkers that can predict the efficacy of Sorafenib against HCC. Biomarkers that could predict the likely benefits of Sorafenib in a specific patient would greatly help doctors make clinical decisions [25].

The pERK protein is a key downstream factor of the MEK/ERK cascade signaling pathway. Although this is an intuitive potential biomarker candidate, the present evidence (either in vitro or in vivo) to support using pERK as a predictive marker for Sorafenib in HCC therapy is preliminary. Zhang et al. evaluated the effects of Sorafenib on cell proliferation by cell viability assays in SMMC-7721, MHCC97-L, MHCC97-H and HCCLM6, and thought that basal pERK expression levels were an important factor in Sorafenib efficacy. But in vivo experiments were lacking. We found previously that anti-PD-1 immunotherapy might complement Sorafenib in treating HCC patients. We had also identified that pERK would help HCC patient selection to achieve optimal clinical benefits. To examine the efficacy of Sorafenib on individual tumors, we generated patient-derived xenografts using surgically removed HCC tissue. Unfortunately, we could only recruit three pairs of patient-derived primary HCC xenografts at that time, and our results may have suffered from selection bias [26].

In this study, we assessed the activity of the RAF/MEK/ERK pathway in different HCC cell lines and HCC tissues from patients. Both Immunohistochemistry and Western blotting were used to determine the intracellular expression of pERK. In cell killing assays, Sorafenib inhibited proliferation of cancer cells with different pERK expression in a dose-dependent manner. That the efficacy of Sorafenib is correlated with basal intracellular pERK levels was shown by correlation analysis between the IC50 values and the pERK density values, indicating that Sorafenib efficacy was closely related to the activity of the RAF/MEK/ERK signaling pathway in HCC tumor cells. This is consistent with

---

**Table 2. Genes with high expression in HCC-0010 cell lines.**

| Gene       | Chromosome Location | Associated Pathway       | Fold_change (HCC-0010/HepG2) | P value   |
|------------|---------------------|--------------------------|------------------------------|-----------|
| TGFB2      | chr1                | ALK_PATHWAY              | 295                          | 2.51E-05  |
| BMP2       | chr20               |                          | 1564                         | 3.38E-13  |
| NPPB       | chr1                |                          | 175                          | 8.50E-08  |
| NSD1       | chr5                | Lysinedegradation        | 576                          | 1.03E-05  |
| SETD7      | chr4                |                          | 276                          | 7.77E-09  |
| CD44       | chr11               | ECM-receptorinteraction  | 280                          | 2.72E-05  |
| LAMC2      | chr1                |                          | 1250                         | 2.27E-07  |

1Changes of gene expression over 150-fold.

---
the recent findings of the Zhang et al. in vitro study and our previous study [26, 27]. To explore the underlying mechanisms, we carried out RNA-seq to discover gene expression changes with Sorafenib treatment in HCC cell lines that differentially express pERK (HepG2 and HCC-0010). We found out that there were significantly more genes whose expression levels changed over fourfold after Sorafenib treatment in the HepG2 cells relative to HCC-0010 cells (Table 1). More interestingly, we also observed similar gene expression patterns in several important tumor-associated pathways including the ALK pathway ([TGFβ2, BMP2, NPPB and others] [15, 16], Lysine degradation ([NSD1, SETD7 and others]) [17] and ECM-receptor interaction ([CD44, LAMC2 and others]) [18] showed dramatically higher levels of expression in HCC-0010 cells compared with HepG2 cells (Table 2). This might explain the different sensitivity of Sorafenib between HCC-0010 and HepG2 cell lines. Sun et al. reported that HCC cells that are characterized by active epithelial-mesenchymal transition (EMT) exhibit increased drug resistance, whereas SB-431542, an antagonist of activin receptor-like kinase (ALK) receptors, attenuates EMT in HCC cells [28]. Huang et al. report that the activity of lysine-specific histone demethylase 1A is required for the emergence of cancer cells following Sorafenib treatment, suggesting that KDM1A inhibitors may be utilized to alleviate acquired resistance to Sorafenib, thus increasing the therapeutic efficacy of Sorafenib in HCC patients [29]. Fernando et al. described that the mesenchymal profile and expression of CD44, linked to activation of the TGF-β pathway, may predict the poor response to Sorafenib in HCC patients [30]. Govaere et al. identified a prominent role for laminin-332, encoded by LAMC2, as part of the specialized CSC niche in maintaining and supporting cell stemness, which leads to chemo-resistance [31]. We used real-time qPCR to verify the results of RNA-seq in human tissues, and showed that Lysine degradation associated genes ([NSD1 and SETD7]) were expressed at dramatically higher levels in HCC-0010 cells than in HepG2 cells. Down regulation of SETD7 increased the sensitivity of HCC to Sorafenib, indicating that SETD7 may be the key factor of Sorafenib resistance in HCC. As a methyltransferase for H3K4, SETD7 plays an important role in inflammation and oncogenesis. However, the functions and mechanisms of SETD7 in HCC remain poorly understood. Chen et al. reported that SETD7 overexpression can promote HepG2 cell proliferation, whereas SETD7 knockdown can inhibit SMMC-7721 cell proliferation by regulating the cell cycle, indicating that SETD7 plays a critical role in HCC [32]. The immunohistochemistry signature of SETD7 may provide a clinical tool for personalized therapy of HCC patients treated with Sorafenib.

Only 30.3% (20 out of 66) patient samples from Chinese ethnicity showed high pERK expression. RNA-seq data suggested that different HCC cell lines (HCC-0010 (Chinese origin cells)) and HepG2 (Caucasian origin cells) involve different tumor-associated pathways, which partly explain the ethnic differences in Sorafenib efficacy. In our opinion, the pERK signal pathway is not a key tumor-associated pathway in some Chinese HCC patients, and these patients will not benefit from taking Sorafenib.

To support our hypothesis in vivo, we established patient-derived xenografts on mice. Preliminary studies demonstrated that the mouse model exhibits tissue and cellular characteristics that resemble human tumors [33, 34]. Our investigations revealed that the growth rates of tumors with high levels of pERK expression in patient-derived xenografts were significantly decreased by Sorafenib treatment, while the tumor with low or no expression of pERK did not react to Sorafenib. We previously reported results from 3 pairs of patient-derived xenografts [26]. Here, we recruited another 5 pairs of xenografts, originated from 10 different patients for further in vivo validation. Unfortunately, we are still limited by the availability of different patient-derived xenografts.

In summary, this research further supports, in vitro and in vivo, that pERK could be a useful biomarker to predict the actions of Sorafenib, and partly explains the ethnic differences in its efficacy, providing a basis for personalized medicine.

Acknowledgment

We thank C. Yong who provided the Primary cell HCC-0010 culture and helped to carry out the RNA-seq.

Conflict of Interest

We declare that no competing of interest and conflicts of ethics involved in the manuscript.

References

1. Bosch, F. X., J. Ribes, M. Diaz, and R. Cleries. 2004. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127:S5–S16.
2. El-Serag, H. B. 2011. Hepatocellular carcinoma. N. Engl. J. Med. 365:1118–1127.
3. Bruix, J., L. Boix, M. Sala, and J. M. Llovet. 2004. Focus on hepatocellular carcinoma. Cancer Cell 5:215–219.
4. El-Serag, H. B., and K. L. Rudolph. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576.
5. Vogel, C. L., M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, et al. 2002.
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20:719–726.

6. Cobleigh, M. A., C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, et al. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639–2648.

7. Jordan, V. C., and B. W. O’Malley. 2007. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25:5815–5824.

8. Patil, N., M. Abba, and H. Allgayer. 2012. Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics 6:221–231.

9. Cheng, A. L., Y. K. Kang, Z. Chen, C. J. Tsao, S. Qin, J. S. Kim, et al. 2009. Efficacy and safety of Sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.

10. Llovet, J. M., S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. F. Blanc, et al. 2008. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359:378–390.

11. Furuse, J. 2008. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics 2:779–788.

12. Greten, T. F., F. Korangy, M. P. Manns, and N. P. Malek. 2009. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer 100:19–23.

13. Carr, B. L., S. Carroll, N. Muszbek, and K. Gondek. 2010. Economic evaluation of Sorafenib in unresectable hepatocellular carcinoma. J. Gastroenterol. Hepatol. 25:1739–1746.

14. Schor-Bardach, R., D. C. Alsop, I. Pedrosa, S. A. Solazzo, X. Wang, R. P. Marquis, et al. 2009. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 251:731–742.

15. Murakami, M., H. Kawachi, K. Ogawa, Y. Nishino, and M. Funaba. 2009. Receptor expression modulates the specificity of transforming growth factor-beta signaling pathways. Genes Cells 14:469–482.

16. Olsson, N., E. Pick, P. ten Dijke, and G. Nilsson. 2000. Human mast cell migration in response to members of the transforming growth factor-beta family. J. Leukoc. Biol. 67:350–356.

17. Carr, S. M., and N. B. La Thangue. 2011. Cell cycle control by a methylation-phosphorylation switch. Cell Cycle 10:733–734.

18. Ghosh, S. C., S. Neslihan Alpay, and J. Klostergaard. 2012. CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin. Ther. Targets 16:635–650.

19. Farazi, P. A., and R. A. DePinho. 2006. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6:674–687.

20. Chappell, W. H., L. S. Steelman, J. M. Long, R. C. Kempf, S. L. Abrams, R. A. Franklin, et al. 2011. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135–164.

21. Nottage, M., and L. L. Siu. 2002. Rationale for Ras and Raf-kinase as a target for cancer therapeutics. Curr. Pharm. Des. 8:2231–2242.

22. O’Neill, E., and W. Kolch. 2004. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br. J. Cancer 90:283–288.

23. Lyons, J. F., S. Wilhelm, B. Hibner, and G. Bollag. 2001. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8:219–225.

24. Wilhelm, S. M., C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109.

25. McShane, L. M., D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, and G. M. Clark. 2005. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 23:9067–9072.

26. Chen, J., T. Ji, J. Zhao, G. Li, J. Zhang, R. Jin, et al. 2012. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. Oncotarget 7:41274–84.

27. Zhang, Z., X. Zhou, H. Shen, D. Wang, and Y. Wang. 2009. Phosphorylated ERK is a potential predictor of sensitivity to Sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 7:41.

28. Sun, C., L. Sun, K. Jiang, D. M. Gao, X. N. Kang, C. Wang, et al. 2013. NANO2 promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int. J. Biochem. Cell Biol. 45:1099–1108.

29. Huang, M., C. Chen, J. Geng, D. Han, T. Wang, T. Xie, et al. 2017. Targeting KDM1A attenuates Wnt/b-catenin signaling pathway to eliminate Sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 10:12–21.

30. Fernando, J., A. Malfettone, E. B. Cepeda, R. Vilarrasa-Blasi, E. Bertran, G. Raimondi, et al. 2015. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to Sorafenib in liver tumor cells. Int. J. Cancer 136:E161–E172.
31. Govaere, O., J. Wouters, M. Petz, Y. P. Vandewynckel, K. Van den Eynde, A. Van den Broeck, et al. 2016. Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. J. Hepatol. 64:609–17.

32. Chen, Y., S. Yang, J. Hu, C. Yu, M. He, and Z. Cai. 2016. Increased expression of SETD7 promotes cell proliferation by regulating cell cycle and indicates poor prognosis in hepatocellular carcinoma. PLoS ONE 11:e0154939.

33. Huynh, H., P. K. Chow, N. Palanisamy, M. Salto-Tellez, B. C. Goh, C. K. Lee, et al. 2008. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J. Hepatol. 49:52–60.

34. Huynh, H., K. H. Chow, K. C. Soo, H. C. Toh, S. P. Choo, K. F. Foo, et al. 2009. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J. Cell Mol. Med. 13:1371–1380.